Treatments and prognostic factors for bone and soft tissue sarcoma in non-urban areas in Japan.
Bone and soft tissue sarcoma
Non-urban area
Prognostic factors
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
28 Dec 2023
28 Dec 2023
Historique:
received:
07
08
2023
accepted:
05
12
2023
medline:
29
12
2023
pubmed:
29
12
2023
entrez:
28
12
2023
Statut:
aheadofprint
Résumé
Although bone and soft tissue sarcoma is recognized as a rare cancer that originates throughout the body, few comprehensive reports regarding it have been published in Japan. Bone and soft tissue sarcomas were tabulated from the Cancer Registries at eight university hospitals in the Chugoku-Shikoku region. Prognostic factors in cases were extracted in a single facility and have been analyzed. From 2016 to 2019, 3.4 patients with bone and soft tissue sarcomas per a general population of 100,000 were treated at eight university hospitals. The number of patients who underwent multidisciplinary treatment involving collaboration among multiple clinical departments has been increasing recently. In the analysis carried out at a single institute (Ehime University Hospital), a total of 127 patients (male/female: 54/73) with an average age of 67.0 y (median 69.5) were treated for four years, with a 5-year survival rate of 55.0%. In the analysis of prognostic factors by multivariate, disease stage and its relative treatment, renal function (creatinine), and a patient's ability of self-judgment, and a patient's mobility and physical capability were associated with patient prognosis regarding bone and soft tissue sarcomas. Interestingly, age did not affect the patient's prognosis (> 70 vs ≦ 70). Physical and social factors may affect the prognosis of patients with bone and soft tissue sarcomas, especially those living in non-urban areas.
Sections du résumé
BACKGROUND
BACKGROUND
Although bone and soft tissue sarcoma is recognized as a rare cancer that originates throughout the body, few comprehensive reports regarding it have been published in Japan.
PATIENTS AND METHODS
METHODS
Bone and soft tissue sarcomas were tabulated from the Cancer Registries at eight university hospitals in the Chugoku-Shikoku region. Prognostic factors in cases were extracted in a single facility and have been analyzed.
RESULTS
RESULTS
From 2016 to 2019, 3.4 patients with bone and soft tissue sarcomas per a general population of 100,000 were treated at eight university hospitals. The number of patients who underwent multidisciplinary treatment involving collaboration among multiple clinical departments has been increasing recently. In the analysis carried out at a single institute (Ehime University Hospital), a total of 127 patients (male/female: 54/73) with an average age of 67.0 y (median 69.5) were treated for four years, with a 5-year survival rate of 55.0%. In the analysis of prognostic factors by multivariate, disease stage and its relative treatment, renal function (creatinine), and a patient's ability of self-judgment, and a patient's mobility and physical capability were associated with patient prognosis regarding bone and soft tissue sarcomas. Interestingly, age did not affect the patient's prognosis (> 70 vs ≦ 70).
CONCLUSIONS
CONCLUSIONS
Physical and social factors may affect the prognosis of patients with bone and soft tissue sarcomas, especially those living in non-urban areas.
Identifiants
pubmed: 38155238
doi: 10.1007/s10147-023-02453-4
pii: 10.1007/s10147-023-02453-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
Références
Ogura K, Higashi T, Kawai A (2017) Statistics of soft-tissue sarcoma in Japan: report from the Bone and Soft Tissue Tumor Registry in Japan. J Orthop Sci 22:755–764. https://doi.org/10.1016/j.jos.2017.03.017
doi: 10.1016/j.jos.2017.03.017
pubmed: 28601416
Ferrari A, Sultan I, Huang TT et al (2011) Soft tissue sarcomas across the age spectrum: a population-based study from the surveillance epidemiology and end results database. Pediatr Blood Cancer 57:943–949. https://doi.org/10.1002/pbc.23252
doi: 10.1002/pbc.23252
pubmed: 21793180
pmcid: 4261144
Wibmer C, Leithner A, Zielonke N et al (2010) Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review. Ann Oncol 21:1106–1111. https://doi.org/10.1093/annonc/mdp415
doi: 10.1093/annonc/mdp415
pubmed: 19858086
Nakayama R, Mori T, Okita Y et al (2020) A multidisciplinary approach to soft-tissue sarcoma of the extremities. Expert Rev Anticancer Ther 20:893–900. https://doi.org/10.1080/14737140.2020.1814150
doi: 10.1080/14737140.2020.1814150
pubmed: 32820961
D’Adamo DR (2011) Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol 38:19–29. https://doi.org/10.1053/j.seminoncol.2011.09.004
doi: 10.1053/j.seminoncol.2011.09.004
Blay JY, Sleijfer S, Schöffski P et al (2014) International expert opinion on patient-tailored management of soft tissue sarcomas. Eur J Cancer 50:679–689. https://doi.org/10.1016/j.ejca.2013.11.011
doi: 10.1016/j.ejca.2013.11.011
pubmed: 24295638
Bagaria SP, Wagie AE, Gray R et al (2015) Validation of a soft tissue sarcoma nomogram using a national cancer registry. Ann Surg Oncol 22:398–403. https://doi.org/10.1245/s10434-015-4849-9
doi: 10.1245/s10434-015-4849-9
Callegaro D, Miceli R, Bonvalot S et al (2016) Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol 17:671–680. https://doi.org/10.1016/S1470-2045(16)00010-3
doi: 10.1016/S1470-2045(16)00010-3
pubmed: 27068860
Sekimizu M, Ogura K, Yasunaga H et al (2019) Development of nomograms for prognostication of patients with primary soft tissue sarcomas of the trunk and extremity: report from the Bone and Soft Tissue Tumor Registry in Japan. BMC Cancer 19:657–668. https://doi.org/10.1186/s12885-019-5875-y
doi: 10.1186/s12885-019-5875-y
pubmed: 31272407
pmcid: 6610844
Kuntz CA, Dernell WS, Powers BE et al (1997) Prognostic factors for surgical treatment of soft-tissue sarcomas in dogs: 75 cases (1986–1996). J Am Vet Med Assoc 211:1147–1151
doi: 10.2460/javma.1997.211.09.1147
pubmed: 9364229
Schoffski P, Chawla S, Maki RG et al (2016) Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387:1629–1637. https://doi.org/10.1016/S0140-6736(15)01283-0
doi: 10.1016/S0140-6736(15)01283-0
pubmed: 26874885
Demetri GD, von Mehren M, Jones R et al (2016) Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 34:786–793. https://doi.org/10.1200/JCO.2015.62.4734
doi: 10.1200/JCO.2015.62.4734
pubmed: 26371143
Kawai A, Araki N, Sugiura H et al (2015) Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol 16:406–416. https://doi.org/10.1016/S1470-2045(15)70098-7
doi: 10.1016/S1470-2045(15)70098-7
pubmed: 25795406
van der Graaf WTA, Blay JY, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886. https://doi.org/10.1016/S0140-6736(12)60651-5
doi: 10.1016/S0140-6736(12)60651-5
pubmed: 22595799
Kyriazoglou A, Gkaralea LE, Kotsantis L et al (2022) Tyrosine kinase inhibitors in sarcoma treatment. Oncol Lett 23:183. https://doi.org/10.3892/ol.2022.13303
doi: 10.3892/ol.2022.13303
pubmed: 35527786
pmcid: 9073578
Saerens M, Brusselaers N, Rottey S et al (2021) Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: a systematic review and meta-analysis. Eur J Cancer 152:165–182. https://doi.org/10.1016/j.ejca.2021.04.034
doi: 10.1016/j.ejca.2021.04.034
pubmed: 34107450
Brundisini F, Giacomini M, DeJean D et al (2013) Chronic disease patients’ experiences with accessing health care in rural and remote areas: a systematic review and qualitative meta-synthesis. Ont Health Technol Assess Ser 13:1–33
pubmed: 24228080
pmcid: 3817950
Coughlin SS (2020) Social determinants of colorectal cancer risk, stage, and survival: a systematic review. Int J Colorectal Dis 35:985–995. https://doi.org/10.1007/s00384-020-03585-z
doi: 10.1007/s00384-020-03585-z
pubmed: 32314192
Paredes TF, Canavarro MC, Simões MR (2012) Social support and adjustment in patients with sarcoma: the moderator effect of the disease phase. J Psychosoc Oncol 30:402–425. https://doi.org/10.1080/07347332.2012.684852
doi: 10.1080/07347332.2012.684852
pubmed: 22747105
Storey L, Fern LA, Martins A, et al (2019) A critical review of the impact of sarcoma on psychosocial wellbeing. Sarcoma. 17: 9730867 https://doi.org/10.1155/2019/9730867